Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer

2 min read | December 22, 2025 02:53 AM PST | By Team Kalkine Media

Google News:

Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer — Image source: © 2025 Krish Capital Pty. Ltd.

Recent News

Precious Metal Micro-Caps Gain Focus as Silver Deficit Deepens

Why This US Penny Stock Faces A Critical Test In The EV Market?

Tilray Brands and Aurora Cannabis Draw Fresh Penny Stock Buzz

Can Low-Cost Oil Producers Stay Ahead As Supply Pressure Builds?

Make Kalkine Media
My Trusted Source

Highlights
• Japan approves Zynyz with chemotherapy for first-line treatment of advanced anal cancer
• First approval for Zynyz in Japan and second globally for this indication
• Decision supported by Phase 3 POD1UM-303 clinical trial data

Incyte Biosciences Japan G.K. (NASDAQ:INCY) has announced that Japan’s Ministry of Health, Labour and Welfare has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).

This approval marks the first regulatory clearance for Zynyz in Japan and expands the approved use of the therapy in advanced anal cancer.

Clinical Evidence

The approval is based on results from the global Phase 3 POD1UM-303/InterAACT2 trial, which evaluated retifanlimab plus chemotherapy against chemotherapy alone. The study demonstrated a statistically significant reduction in the risk of disease progression or death, along with improved progression-free survival.

Zynyz is a humanized monoclonal antibody targeting the PD-1 receptor and is administered intravenously.

Treatment Context

SCAC is a rare cancer with limited first-line treatment options in the metastatic setting. The approval allows the use of an immunotherapy-based combination earlier in the treatment pathway for eligible patients in Japan.

Management Commentary

Yasuyuki Ishida, General Manager of Incyte Biosciences Japan G.K., said:

“Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC.”

The closing price of INCY was USD 102.69 as of December 19, 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.